Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments
Niloufar Pouyan, Jacob S. Aday, Steven E. Harte, Chelsea M Kaplan, David A Williams, Nicolas G. Glynos, Moss Herberholz, Daniel J. Kruger, Julie Barron, George A. Mashour, Daniel J. Clauw, Katrin H. Preller, Andrew Schrepf, Kevin F. Boehnke
Universität Zürich, ZORA May 1, 2025 DOI: 10.5167/uzh-284302 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective survey Peer reviewed |
|---|---|
| Sample size | 297 |
| Population | Individuals who self-engaged in naturalistic psychedelic use for therapeutic purposes |
| Intervention | naturalistic psychedelic use |
| Topics | Anxiety |
| Keywords | Perception Depression economics Naturalistic observation Predictive validity Clinical global impression Clinical psychology Psychotherapist |
| Key findings | Reductions in self-condition enmeshment, measured by PRISM, were associated with symptom improvement across depression, PTSD, and anxiety following naturalistic psychedelic use. |
Abstract
Background: Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial representation of illness and self measure (PRISM) is a tool used to assess the enmeshment of individuals' perception of self with a particular medical condition, broadly termed self-condition enmeshment.
Aims: This study aimed to evaluate changes in PRISM scores and how these changes relate to symptom changes following naturalistic psychedelic use.
Methods: In this survey, we retrospectively assessed changes in PRISM scores in 297 individuals who self-engaged in naturalistic psychedelic use for therapeutic purposes. Participants also completed the Patient Global Impression of Change (PGIC) scale to report symptom changes resulting from their perceived most salient psychedelic experience (MSPE).
Results: PGIC scores indicated that the majority of participants with depression (95.4%), posttraumatic stress disorder (98.36%), and anxiety (94.87%) reported symptom improvement following naturalistic psychedelic use. There was a significant decrease ( = 4.65 × 10) in PRISM scores after MSPE compared to their PRISM scores before MSPE, indicating that individuals experienced a reduced identification of their identity with their condition following psychedelic use. PRISM change scores were also correlated with PGIC scores across all conditions (ρ = 0.41, = 1.64 × 10), indicating that reductions in self-condition enmeshment were associated with symptom improvement.
Conclusions: Our results suggest that PRISM has transdiagnostic sensitivity for investigating the effects of psychedelics on self-perception. Interpretation is limited by convenience sampling, potential positive bias, retrospective reporting, and unclear doses and settings with natural psychedelic use.
Comparable studies
Other cross-sectional and survey studies on anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. International sample of people who reported having used a psychedelic | 2020 | Cross-sectional survey | n = 985 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users Ecstasy users who participated in a WWW study of recreational drug use | 2002 | Cross-sectional survey | n = 282 |
| 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Adults who used 5-MeO-DMT in a group setting with structured procedures | 2019 | Cross-sectional survey | n = 362 |